Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan

被引:14
|
作者
Hsu, Ching-Sheng
Liu, Chun-Jen
Lai, Ming-Yang
Chen, Pei-Jer
Kao, Jia-Horng
Chen, Ding-Shinn
机构
[1] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei 100, Taiwan
[2] Buddhist Tzu Chi Gen Hosp, Dept Hepatogastroenterol, Dept Internal Med, Taipei Branch, Taipei, Taiwan
[3] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Coll Med, Dept Med Res, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Coll Med, Hepatitis Res Ctr, Taipei 10764, Taiwan
[6] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan
关键词
hepatitis C virus; viral kinetics; pegylated interferon; interferon; ribavirin;
D O I
10.1159/000105444
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objectives: Early hepatitis C viral ( HCV) kinetics following pegylated interferon-alpha (PEG-IFN) and ribavirin help to assess treatment in the Western world. Whether this functions in Taiwanese patients remains unknown. Studying the early HCV kinetics in Taiwanese patients may clarify this issue. Methods: Six chronic hepatitis C patients were enrolled. A PEG-IFN-alpha dose was administered at week 1, then it was administered weekly with daily ribavirin for 24 weeks. Serum HCV RNA levels were determined frequently during the trial and qualitatively at week 49. Kinetic parameters epsilon ( effectiveness at inhibiting viral production) and delta ( loss rate of infected cells) were estimated from viral loads and alanine aminotransferase ( ALT) kinetics, respectively. Results: All serum HCV RNA levels became undetectable at week 12. The epsilon ranged from 0.4128 to 0.9904 and delta from 0.0019 to 0.1245. The log values of viral load differences between day 7 and 14 ranged from 0.15 to 1.21. Only 1 patient had an abnormal ALT level at week 49. Conclusions: Viral kinetic parameters in Taiwanese patients were similar to those in Western studies. However, the early viral decline pattern and viral negativity rate in Taiwanese patients might be different from Caucasian patients. Further large-scale studies to clarify this issue are ongoing. Copyright (C) 2007 S. Karger AG, Basel.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 50 条
  • [31] Soluble TRAIL levels decreased in chronic hepatitis C treatment with pegylated interferon α plus ribavirin: association with viral responses
    Seyman, Derya
    Yalcin, Arzu Didem
    Oztoprak, Nefise
    Genc, Gizem Esra
    Ozen, Nevgun Sepin
    Kizilates, Filiz
    Berk, Hande
    Gumuslu, Saadet
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 7 (12): : 5650 - 5656
  • [32] Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan
    Chang, Yu-Kang
    Tseng, Yuan-Tsung
    Chen, Kou-Huang
    Chen, Kow-Tong
    BMC ENDOCRINE DISORDERS, 2019, 19 (1)
  • [33] Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
    Carvalho-Filho, Roberto J.
    Dalgard, Olav
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2010, 3 : 1 - 13
  • [34] Pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients
    Moreno, L
    Quereda, C
    Moreno, A
    Perez-Elías, MJ
    Antela, A
    Casado, JL
    Dronda, F
    Mateos, ML
    Bárcena, R
    Moreno, S
    AIDS, 2004, 18 (01) : 67 - 73
  • [35] Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan
    Yu-Kang Chang
    Yuan-Tsung Tseng
    Kou-Huang Chen
    Kow-Tong Chen
    BMC Endocrine Disorders, 19
  • [36] Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis
    Camma, Calogero
    Cabibbo, Giuseppe
    Bronte, Fabrizio
    Enea, Marco
    Licata, Anna
    Attanasio, Massimo
    Andriulli, Angelo
    Craxi, Antonio
    JOURNAL OF HEPATOLOGY, 2009, 51 (04) : 675 - 681
  • [37] Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan
    Lai, MY
    INTERVIROLOGY, 2005, 49 (1-2) : 91 - 95
  • [38] Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection
    Maughan, Ashly
    Ogbuagu, Onyema
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (02) : 219 - 227
  • [39] Haematological side effects in patients with chronic viral hepatitis C during treatment with alpha interferon and ribavirin
    Ciesla, Andrzej
    Mach, Tomasz
    Zejc-Bajsarowicz, Malgorzata
    Sobczyk-Krupiarz, Iwona
    Warunek, Wioleta
    Janas-Skulina, Urszula
    Glowacki, Mikolaj
    Baczynska, Ewelina
    Banas, Wojciech
    Talaga, Katarzyna
    PRZEGLAD GASTROENTEROLOGICZNY, 2007, 2 (02): : 74 - 78
  • [40] Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment
    Takashima, Tomoyuki
    Enomoto, Hirayuki
    Ninomiya, Toshiaki
    Kim, Soo Ryang
    Okushin, Hiroaki
    Sugano, Masahiko
    Imoto, Susumu
    Yano, Yoshihiko
    Ooka, Teruji
    Seo, Yasushi
    Kasugai, Hiroshi
    Muramatsu, Akira
    Jomura, Hisato
    Shimomura, Soji
    Shindo, Michiko
    Nakamura, Hideji
    Aizawa, Nobuhiro
    Iwata, Yoshinori
    Saito, Masaki
    Imanishi, Hiroyasu
    Iijma, Hiroko
    Nishiguchi, Shuhei
    HEPATOLOGY RESEARCH, 2014, 44 (06) : 597 - 607